X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22

    Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS

    Full service: the expertise and efficiency of a one-stop shop

    Full service: the expertise and efficiency of a one-stop shop

    UCB and Microsoft expand drug development partnership

    UCB and Microsoft expand drug development partnership

    Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer's disease

    Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer’s disease

    Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma

    AstraZeneca and IDT Biologika sign LOI to increase COVID-19 vaccine manufacturing in Europe and secure long-term supply capacity

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

    GSK and CureVac to develop next generation mRNA COVID-19 vaccines

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22

    Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS

    Full service: the expertise and efficiency of a one-stop shop

    Full service: the expertise and efficiency of a one-stop shop

    UCB and Microsoft expand drug development partnership

    UCB and Microsoft expand drug development partnership

    Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer's disease

    Exscientia and the University of Oxford announce partnership to develop treatments for Alzheimer’s disease

    Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma

    AstraZeneca and IDT Biologika sign LOI to increase COVID-19 vaccine manufacturing in Europe and secure long-term supply capacity

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate

    Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

    GSK and CureVac to develop next generation mRNA COVID-19 vaccines

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Clinical Trials

Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS

Content Team by Content Team
3rd March 2021
in Clinical Trials, Drug Development, News
Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22

Cerecor Inc., a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, today announced final efficacy data including 60-day mortality from their recently completed US-based, multi-center (10 sites), Phase 2 trial (NCT04412057) of the human anti-LIGHT (TNFSF14) monoclonal antibody CERC-002. This analysis updates the preliminary topline data reported on January 5, 2021. All patients in this trial were hospitalized with COVID-19 associated pneumonia and mild-to-moderate acute respiratory distress syndrome (“ARDS”). A total of 83 patients were randomized 1:1 to receive standard of care at the sites plus either a single dose of 1,200 mg of CERC-002 or placebo subcutaneously. Due to the protocol allowing patients to receive high flow oxygen prior to randomization, 62 patients were included in the intention-to-treat (ITT) analysis of the primary endpoint.

The final analysis inclusive of the 60-day safety update demonstrated the trial met its primary efficacy endpoint (proportion of patients alive and free of respiratory failure over the 28-day study period) compared to placebo in COVID-19 patients with ARDS treated with a single dose of the anti-LIGHT monoclonal antibody CERC-002 (n=62, p=0.044). Efficacy was highest in a prespecified subpopulation of patients over the age of 60 (n=34, p=0.042), the population most vulnerable to severe complications and death with COVID-19 infection.

At both the 28-day and the 60-day final timepoints, an approximately 50% trend in mortality reduction (22.5% vs 10.8%) was observed.

CERC-002 showed statistically significant efficacy on top of corticosteroids and standard of care treatments in COVID-19 ARDS: over 90% of patients received concomitant systemic corticosteroids and over 65% received remdesivir. CERC-002 was well-tolerated. No drug-related serious adverse effects (SAEs) were reported in the trial, and there was no increase in infections in CERC-002 treated patients.

Cerecor has submitted applications to the U.S. Food and Drug Administration (FDA) for Breakthrough Therapy and Fast Track Designations. The Company plans to meet with FDA to discuss the potential path to Emergency Use Authorization (EUA) and approval.

“We would like to thank the patients who participated in this landmark study. These results not only validate our hypothesis that elevated LIGHT is a key driver of morbidity and mortality in COVID-19 ARDS1, but also provide strong initial evidence that LIGHT neutralization with CERC-002 in this setting may be able to save lives and can spare patients from the need for ventilatory support,” said H. Jeffrey Wilkins, MD, Chief Medical Officer of Cerecor. “These results are all the more encouraging given that this novel targeted therapy demonstrated efficacy and excellent tolerability despite being administered over and above standard of care including high dose systemic corticosteroids.”

“Despite progress with vaccinations, thousands of people in the US and around the world continue to die of COVID-19 related cytokine release syndrome and ARDS every day. There is an urgent need for new safe and effective therapies to treat these patients,” said Dr. David Perlin, Ph.D., Chief Scientific Officer and Senior Vice President of the Center for Discovery and Innovation at the Hackensack Meridian School of Medicine. “The need is all the greater given the increasing levels of COVID-19 mutation and resistance emerging in variants. Even with widespread vaccination such therapies will be required for many years to come.”

 

Previous Post

Merck to Help Produce Johnson & Johnson's COVID-19 Vaccine

Next Post

Peli BioThermal Announces Latest Distributor Partnerships

Related Posts

Peli BioThermal Announces Latest Distributor Partnerships
News

Peli BioThermal Announces Latest Distributor Partnerships

3rd March 2021
U.S. FDA confirms Pfizer COVID vaccine safe & effective
News

Merck to Help Produce Johnson & Johnson’s COVID-19 Vaccine

3rd March 2021
NovalGen Enters Strategic Partnership with HALIX B.V. to Manufacture Clinical Trial Materials
News

NovalGen Enters Strategic Partnership with HALIX B.V. to Manufacture Clinical Trial Materials

3rd March 2021
DHL expands pharma capabilities in South Africa
News

DHL Express partners with MASkargo to deliver first batch of Covid-19 vaccines to Malaysia

3rd March 2021
Full service: the expertise and efficiency of a one-stop shop
Drug Development

Full service: the expertise and efficiency of a one-stop shop

26th February 2021
Vetter continues its successful performance at the 2021 CMO Leadership Awards
News

Vetter continues its successful performance at the 2021 CMO Leadership Awards

25th February 2021
Next Post
Peli BioThermal Announces Latest Distributor Partnerships

Peli BioThermal Announces Latest Distributor Partnerships

Latest News

Aptar Pharma and Noble Partner with dne pharma, a European Leader in Addiction Medicine, on Ventizolve Nasal Naloxone Treatment
Press Statements

Aptar Pharma and Noble Partner with dne pharma, a European Leader in Addiction Medicine, on Ventizolve Nasal Naloxone Treatment

16th March 2021
Peli BioThermal Announces Latest Distributor Partnerships
News

Peli BioThermal Announces Latest Distributor Partnerships

3rd March 2021
Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22
Clinical Trials

Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS

3rd March 2021
U.S. FDA confirms Pfizer COVID vaccine safe & effective
News

Merck to Help Produce Johnson & Johnson’s COVID-19 Vaccine

3rd March 2021
Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use
Press Statements

Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use

3rd March 2021
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In